JWCA
HRTX icon

J.W. Cole Advisors’s Heron Therapeutics HRTX Stock Holding History

J.W. Cole Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.4K Buy
+15,000
New +$12K ﹤0.01% 1592
2026
Q1 		– Sell
-16,000
Closed -$20.8K – 1064
2025
Q4 		$20.8K Hold
16,000
– – ﹤0.01% 1437
2025
Q3 		$20.2K Hold
16,000
– – ﹤0.01% 1536
2025
Q2 		$33.1K Hold
16,000
– – ﹤0.01% 1446
2025
Q1 		$35.2K Buy
16,000
+1,000
+7% +$1.94K ﹤0.01% 1231
2024
Q4 		$22.9K Buy
+15,000
New +$24.3K ﹤0.01% 949

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

J.W. Cole Advisors's HRTX Position: Q2 2026 in Review

J.W. Cole Advisors opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 15,000 shares worth $6.4K. The stake represents ﹤0.01% of the portfolio and ranks #1592 among its holdings. This is a return to the name: J.W. Cole Advisors previously reported a position in HRTX as recently as Q4 2025.

J.W. Cole Advisors first reported a position in HRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $35.2K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • J.W. Cole Advisors held 15,000 shares of Heron Therapeutics worth $6.4K as of Q2 2026.
  • Heron Therapeutics was a new J.W. Cole Advisors position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of J.W. Cole Advisors's portfolio in Q2 2026, its #1592 holding.
  • J.W. Cole Advisors first reported a position in Heron Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • J.W. Cole Advisors's Heron Therapeutics position peaked at $35.2K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on J.W. Cole Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.